All In Biotech

Drug Trial Radar · NCT07840326

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Sundance Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.

Conditions

  • Primary Progressive Multiple Sclerosis
  • Primary Progressive MS
  • Primary Progressive Multiple Sclerosis (PPMS)
  • Secondary Progressive MS (SPMS)
  • Secondary Progressive Multiple Sclerosis (SPMS)
  • Secondary Progressive MS
  • Non-Active SPMS
  • Non-Active Secondary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Interventions

  • SUN-627Drug

    SUN-627, a once daily, orally administered, immediate release tablet

  • PlaceboOther

    Orally-administered matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placeboTime frame: From enrollment to the end of study at 16 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - Site 103

    Tampa, Florida · Recruiting

  • Local Institution - Site 102

    Atlanta, Georgia · Recruiting

  • Local Institution - Site 106

    Stony Brook, New York · Not yet recruiting

  • Local Institution - Site 101

    Raleigh, North Carolina · Recruiting

  • Local Institution - Site 104

    Columbus, Ohio · Recruiting

  • Local Institution - Site 105

    Oklahoma City, Oklahoma · Recruiting

  • Local Institution - Site 107

    Dallas, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.